| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.034 | 0.8 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |